Evidence map›Paper›PMID 32296512›Full record

ArticleEuropean journal of hospital pharmacy : science and practice2020

Ceftolozane-tazobactam in an elastomeric infusion device for ambulatory care: an in vitro stability study.

Edward Raby, Saiyuri Naicker, Fekade Bruck Sime, Laurens Manning, Steven C Wallis, Saurabh Pandey, Jason A Roberts

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of hospital pharmacy : science and practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Exploring the advancements of Australian OPAT.Therapeutic advances in infectious disease
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Edward Raby *Infectious Diseases Department, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.ORCID 0000-0003-1671-6188
Saiyuri Naicker *University Of Queensland Centre for Clinical Research, University of Queensland, Herston, Queensland, Australia.
Fekade Bruck SimeUniversity Of Queensland Centre for Clinical Research, University of Queensland, Herston, Queensland, Australia.
Laurens ManningInfectious Diseases Department, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.
Steven C WallisUniversity Of Queensland Centre for Clinical Research, University of Queensland, Herston, Queensland, Australia.
Saurabh PandeyUniversity Of Queensland Centre for Clinical Research, University of Queensland, Herston, Queensland, Australia.
Jason A RobertsCentre for Translational Anti-infective Pharmacodynamics, Pharmacy Australia Centre of Excellence, Brisbane, Queensland, Australia.
The University of Queensland · AUThe University of Western Australia · AURoyal Brisbane and Women's Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Published in vitro stability data for ceftolozane-tazobactam supports intermittent short duration infusions. This method of delivery is not feasible for many outpatient antimicrobial therapy services that provide only one or two visits per day. This study aimed to assess time, temperature and concentration-dependent stability of ceftolozane-tazobactam in an elastomeric infusion device for continuous infusion across clinically relevant ranges encountered in outpatient antimicrobial therapy. Methods: Ceftolozane-tazobactam was prepared to achieve initial concentrations representing total daily doses for 'renal', 'standard' and 'high' dose schedules in elastomeric infusion devices with a volume of 240 mL. Infusion devices incubated at room and body temperature were serially sampled over 48 hours. Refrigerated infusion devices were sampled over 10 days. Concentrations of ceftolozane and tazobactam were separately quantified using a validated ultra-high performance liquid chromatography-photodiode array method. Results: The greatest loss of ceftolozane occurred at 37°C, however, stability remained above 90% at 24 hours. Tazobactam was more stable than ceftolozane under these conditions. There was minimal loss at 4°C for either component over 7 days. Conclusions: Ceftolozane-tazobactam is suitable for ambulatory care delivered as a continuous infusion via an elastomeric infusion device.

Indexed as

Ambulatory CareAnti-Bacterial AgentsCephalosporinsDrug StabilityElastomersHumansInfusion PumpsTazobactamTemperatureAnti-Bacterial Agentsceftolozane, tazobactam drug combinationCephalosporinsElastomersTazobactamceftolozane–tazobactamclinical pharmacydrug stabilityelastomeric infusion deviceinfectious diseasesoutpatient intravenous antimicrobial therapy

Identifiers

PMID32296512
PMCPMC7147556
OpenAlexW2996357203

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.